IgAN is a key focus for Novartis, driving a decision to acquire Chinook Therapeutics for $3.2 billion upfront earlier this year, adding a pair of late clinical-stage programmes for the disease ...

In January this year Bicycle Therapeutics bolstered its drug development brainpower by recruiting Nicholas Keen to be its chief scientific officer, poaching him from his role as head of Novartis ...

Cerebral venous thrombosis is a rare but potentially life-threatening condition that is particularly prevalent in young women (ie, mean age 44 years) and accounts for 0·5–3% of all strokes. The ...